SAN DIEGO — The significant kidney and cardiovascular benefits people with chronic kidney disease (CKD) show over 2 years of treatment with empagliflozin begin to subside within about a year after ...
THURSDAY, June 26, 2025 (HealthDay News) -- Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial ...
The risk for acute kidney injury was not higher among patients with an eGFR dip at empagliflozin initiation. Previous studies have reported renal benefits with sodium glucose cotransporter 2 inhibitor ...
The FDA has approved new oral therapies for children with type 2 diabetes — empagliflozin and a combination of empagliflozin and metformin hydrochloride — for the first time in more than 20 years. The ...
Announcing a new publication for Acta Materia Medica journal. Sodium-glucose cotransporter 2 inhibitors are a class of glucose-lowering drugs known for robust cardiovascular protective properties.
Intranasal insulin increased mPACC-5, modulated fractional anisotropy and cerebral blood flow. HealthDay News — Intranasal insulin (INI) and empagliflozin are safe and have promising effects on ...
Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function. (HealthDay News) — Empagliflozin has kidney protective effects and reduces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback